Shree Ganesh Remedies Ltd
Shree Ganesh Remedies Ltd Q1 FY26 Results & Presentation Highlights: Revenue ₹24.67 Cr, PAT ₹3.44 Cr
Q1 FY26 investor presentation: what the company reported on revenue, margins and projects.
Based on Shree Ganesh Remedies Ltd's Q1 FY26 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the presentation reports, not management guidance.
The short version
Q1FY26 Revenue from Operations: ₹24.67 crores - Year-on-year (YoY) change in Revenue: -0.45% (slight decline compared to Q1FY25) - Total Income for Q1FY26: ₹25.33 crores, with a marginal YoY increase of 0.02% - The presentation does not provide specific sales volume figures. Q1FY26 EBITDA (excluding other income & exceptional items): ₹7.30 crore - Q1FY26 EBITDA margin: 29.6% (down 321 bps YoY) - Q1FY26 PAT: ₹3.44 crore (down 26.09% YoY) - YoY changes: - EBITDA down 10.19% - PAT down 26.09% - Revenue from operations nearly flat, -0.45% YoY - Explicit margin outlook: - Presentation states EBITDA margins have moderated to a "more normalised and sustainable level" compared to elevated margins seen in prior year, implying margins are expected to stabilize at current levels rather than improve sharply in near term.
From Shree Ganesh Remedies Ltd's Q1 FY26 earnings-call transcript · updated 24 Sept 2026.
Revenue & Sales Performance
- Q1FY26 Revenue from Operations: ₹24.67 crores
- Year-on-year (YoY) change in Revenue: -0.45% (slight decline compared to Q1FY25)
- Total Income for Q1FY26: ₹25.33 crores, with a marginal YoY increase of 0.02%
- The presentation does not provide specific sales volume figures.
- Outlook: Management notes a moderation in growth due to contract repricing in the CRAMS business, European market headwinds, and domestic competition.
- Long-term outlook remains robust with multiple new projects and pipeline strength.
2 more points management made on revenue & sales performance
Profitability & Margins
See what Shree Ganesh Remedies Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Dahej Land Acquisition: 40,554 sq m acquired in 2022 for ₹11 crores; construction of common infrastructure and warehousing initiated; phased expansion planned; multiple projects under evaluation (Page 15).
- Ankleshwar Site Unit 1: Completed Plant 8 CAPEX in FY25; ongoing CAPEX for Plant 7 estimated at ₹15 crores, commissioning expected in FY26; Block 7 design completed and construction accelerated (Pages 13, 32).
- New Pilot Facility: Establishing a pilot plant to expedite execution; slated for completion within Q1FY26 (Page 32).
2 more points management made on capital expenditure plans
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Shree Ganesh Remedies Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points management made on order book & pipeline
Shree Ganesh Remedies Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹33 Cr, net profit ₹6 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Shree Ganesh Remedies Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- NGL Fine Chem Ltd (Q1 FY26)
Q1FY26 Revenue from operations: ₹104.19 crores . Key investor presentation takeaways from NGL Fine Chem Ltd's Q1 FY26 investor presentation — and how it ranks a
- Influx Healthtech Ltd (Q1 FY26)
FY25 revenue from operations: ₹104.9 crores, up 5% YoY from ₹99.9 crores in FY24 (Page 28 & 26). Key investor presentation takeaways from Influx Healthtech Ltd'
- Anuh Pharma Ltd (Q1 FY26)
Operating Revenue for Q1 FY 2026: ₹186.48 Cr, a 35.22% increase year-on-year from ₹137.91 Cr in Q1 FY 2025. Key investor presentation takeaways from Anuh Pharma
- Bharat Parenterals Ltd (Q1 FY26)
Q1 FY 2026 Revenue from Operations (Consolidated):** ₹116.00 crore, up 25.4% YoY from ₹92.51 crore in Q1 FY 2025 (Page 26). Key investor presentation takeaways
Frequently Asked Questions
What were Shree Ganesh Remedies Ltd Q1 FY26 results?
Q1FY26 Revenue from Operations: ₹24.67 crores - Year-on-year (YoY) change in Revenue: -0.45% (slight decline compared to Q1FY25) - Total Income for Q1FY26: ₹25.33 crores, with a marginal YoY increase of 0.02% - The presentation does not provide specific sales volume figures. Q1FY26 EBITDA (excluding other income & exceptional items): ₹7.30 crore - Q1FY26 EBITDA margin: 29.6% (down 321 bps YoY) - Q1FY26 PAT: ₹3.44 crore (down 26.09% YoY) - YoY changes: - EBITDA down 10.19% - PAT down 26.09% - Revenue from operations nearly flat, -0.45% YoY - Explicit margin outlook: - Presentation states EBITDA margins have moderated to a "more normalised and sustainable level" compared to elevated margins seen in prior year, implying margins are expected to stabilize at current levels rather than improve sharply in near term.
What is Shree Ganesh Remedies Ltd share price analysis?
Shree Ganesh Remedies Ltd currently shows a neutral. The stock trades at a P/E of 58.0 with a market cap of ₹896 Cr. Investors should review the full earnings analysis for detailed insights.
Is Shree Ganesh Remedies Ltd planning capital expenditure?
Dahej Land Acquisition: 40,554 sq m acquired in 2022 for ₹11 crores; construction of common infrastructure and warehousing initiated; phased expansion planned; multiple projects under evaluation (Page 15).
Keep Shree Ganesh Remedies Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.